Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorcaserin vs Duloxetine for Oxaliplatin-Induced Peripheral Neuropathy
NCT03812523Phase 2Unknown
- Sponsor
- UNC Health Southeastern
- Start
- Jun 2019
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of lorcaserin in chemotherapy-induced peripheral neuropathy (CIPN), sponsored by UNC Health Southeastern. Primary endpoint: Pain Numerical Rating Scale at 180 days. Status: unknown.
02
Drugs
lorcaserin
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT03812523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03812523.